Emergency 0 9 0 9 O
leukapheresis 10 23 10 23 B-treatment

Emergency 0 9 24 33 B-treatment
treatment 10 19 34 43 I-treatment
for 20 23 44 47 O
hyperleukocytosis 24 41 48 65 B-chronic_disease
with 42 46 66 70 O
hydroxyurea 47 58 71 82 B-treatment
for 59 62 83 86 O
≤ 63 64 87 88 O
10 65 67 89 91 B-upper_bound
days 68 72 92 96 I-upper_bound

Established 0 11 97 108 O
use 12 15 109 112 O
of 16 18 113 115 O
oral 19 23 116 120 B-contraception_consent
, 23 24 120 121 I-contraception_consent
injected 25 33 122 130 I-contraception_consent
or 34 36 131 133 I-contraception_consent
implanted 37 46 134 143 I-contraception_consent
hormonal 47 55 144 152 I-contraception_consent
methods 56 63 153 160 I-contraception_consent
of 64 66 161 163 I-contraception_consent
contraception 67 80 164 177 I-contraception_consent

Female 0 6 178 184 B-gender

Female 0 6 185 191 B-gender
subject 7 14 192 199 I-gender
must 15 19 200 204 O
not 20 23 205 208 O
be 24 26 209 211 O
breastfeeding 27 40 212 225 O
at 41 43 226 228 O
Screening 44 53 229 238 O
or 54 56 239 241 O
during 57 63 242 248 O
the 64 67 249 252 O
study 68 73 253 258 O
period 74 80 259 265 O
, 80 81 265 266 O
and 82 85 267 270 O
for 86 89 271 274 O
60 90 92 275 277 B-upper_bound
days 93 97 278 282 I-upper_bound
after 98 103 283 288 I-upper_bound
the 104 107 289 292 O
final 108 113 293 298 O
study 114 119 299 304 O
drug 120 124 305 309 O
administration 125 139 310 324 O

Female 0 6 325 331 B-gender
subject 7 14 332 339 I-gender
must 15 19 340 344 O
not 20 23 345 348 O
donate 24 30 349 355 O
ova 31 34 356 359 O
starting 35 43 360 368 O
at 44 46 369 371 O
Screening 47 56 372 381 O
and 57 60 382 385 O
throughout 61 71 386 396 O
the 72 75 397 400 O
study 76 81 401 406 O
period 82 88 407 413 O
, 88 89 413 414 O
and 90 93 415 418 O
for 94 97 419 422 O
180 98 101 423 426 B-upper_bound
days 102 106 427 431 I-upper_bound
after 107 112 432 437 I-upper_bound
the 113 116 438 441 O
final 117 122 442 447 O
study 123 128 448 453 B-treatment
drug 129 133 454 458 I-treatment
administration 134 148 459 473 O

Male 0 4 474 478 B-gender
subject 5 12 479 486 I-gender
and 13 16 487 490 O
their 17 22 491 496 O
female 23 29 497 503 B-gender
spouse 30 36 504 510 I-gender
/ 36 37 510 511 I-gender
partners 37 45 511 519 I-gender
who 46 49 520 523 O
are 50 53 524 527 O
of 54 56 528 530 O
childbearing 57 69 531 543 O
potential 70 79 544 553 O
must 80 84 554 558 O
be 85 87 559 561 O
using 88 93 562 567 B-contraception_consent
highly 94 100 568 574 I-contraception_consent
effective 101 110 575 584 I-contraception_consent
contraception 111 124 585 598 I-contraception_consent
consisting 125 135 599 609 I-contraception_consent
of 136 138 610 612 I-contraception_consent
two 139 142 613 616 I-contraception_consent
forms 143 148 617 622 I-contraception_consent
of 149 151 623 625 I-contraception_consent
birth 152 157 626 631 I-contraception_consent
control 158 165 632 639 I-contraception_consent
* 165 166 639 640 I-contraception_consent
( 167 168 641 642 I-contraception_consent
one 168 171 642 645 I-contraception_consent
of 172 174 646 648 I-contraception_consent
which 175 180 649 654 I-contraception_consent
must 181 185 655 659 I-contraception_consent
be 186 188 660 662 I-contraception_consent
a 189 190 663 664 I-contraception_consent
barrier 191 198 665 672 I-contraception_consent
method 199 205 673 679 I-contraception_consent
) 205 206 679 680 I-contraception_consent
starting 207 215 681 689 O
at 216 218 690 692 O
Screening 219 228 693 702 O
and 229 232 703 706 O
continue 233 241 707 715 O
throughout 242 252 716 726 O
the 253 256 727 730 O
study 257 262 731 736 O
period 263 269 737 743 O
and 270 273 744 747 O
for 274 277 748 751 O
120 278 281 752 755 B-upper_bound
days 282 286 756 760 I-upper_bound
after 287 292 761 766 I-upper_bound
the 293 296 767 770 O
final 297 302 771 776 O
study 303 308 777 782 O
drug 309 313 783 787 O
administration 314 328 788 802 O

Male 0 4 803 807 B-gender
subject 5 12 808 815 I-gender
must 13 17 816 820 O
not 18 21 821 824 O
donate 22 28 825 831 O
sperm 29 34 832 837 O
starting 35 43 838 846 O
at 44 46 847 849 O
Screening 47 56 850 859 O
and 57 60 860 863 O
throughout 61 71 864 874 O
the 72 75 875 878 O
study 76 81 879 884 O
period 82 88 885 891 O
and 89 92 892 895 O
for 93 96 896 899 O
120 97 100 900 903 B-upper_bound
days 101 105 904 908 I-upper_bound
after 106 111 909 914 I-upper_bound
the 112 115 915 918 O
final 116 121 919 924 O
study 122 127 925 930 O
drug 128 132 931 935 O
administration 133 147 936 950 O

Placement 0 9 951 960 O
of 10 12 961 963 O
an 13 15 964 966 O
intrauterine 16 28 967 979 B-treatment
device 29 35 980 986 I-treatment
( 36 37 987 988 I-treatment
IUD 37 40 988 991 I-treatment
) 40 41 991 992 I-treatment
or 42 44 993 995 O
intrauterine 45 57 996 1008 B-treatment
system 58 64 1009 1015 I-treatment
( 65 66 1016 1017 I-treatment
IUS 66 69 1017 1020 I-treatment
) 69 70 1020 1021 I-treatment

Preemptive 0 10 1022 1032 B-treatment
treatment 11 20 1033 1042 I-treatment
with 21 25 1043 1047 O
retinoic 26 34 1048 1056 O
acid 35 39 1057 1061 O
prior 40 45 1062 1067 O
to 46 48 1068 1070 O
exclusion 49 58 1071 1080 O
of 59 61 1081 1083 O
APL 62 65 1084 1087 B-clinical_variable
≤ 66 67 1088 1089 O
7 68 69 1090 1091 B-upper_bound
days 70 74 1092 1096 I-upper_bound

Serum 0 5 1097 1102 B-clinical_variable
aspartate 6 15 1103 1112 I-clinical_variable
aminotransferase 16 32 1113 1129 I-clinical_variable
( 33 34 1130 1131 I-clinical_variable
AST 34 37 1131 1134 I-clinical_variable
) 37 38 1134 1135 I-clinical_variable
and 39 42 1136 1139 O
alanine 43 50 1140 1147 B-clinical_variable
aminotransferase 51 67 1148 1164 I-clinical_variable
( 68 69 1165 1166 I-clinical_variable
ALT 69 72 1166 1169 I-clinical_variable
) 72 73 1169 1170 I-clinical_variable
≤ 74 75 1171 1172 O
2.5 76 79 1173 1176 B-upper_bound
x 80 81 1177 1178 I-upper_bound
institutional 82 95 1179 1192 I-upper_bound
upper 96 101 1193 1198 I-upper_bound
limit 102 107 1199 1204 I-upper_bound
normal 108 114 1205 1211 I-upper_bound
( 115 116 1212 1213 I-upper_bound
ULN 116 119 1213 1216 I-upper_bound
) 119 120 1216 1217 I-upper_bound

Serum 0 5 1218 1223 B-clinical_variable
creatinine 6 16 1224 1234 I-clinical_variable
≤ 17 18 1235 1236 O
1.5 19 22 1237 1240 B-upper_bound
x 23 24 1241 1242 I-upper_bound
institutional 25 38 1243 1256 I-upper_bound
ULN 39 42 1257 1260 I-upper_bound
or 43 45 1261 1263 O
an 46 48 1264 1266 O
estimated 49 58 1267 1276 O
glomerular 59 69 1277 1287 B-clinical_variable
filtration 70 80 1288 1298 I-clinical_variable
rate 81 85 1299 1303 I-clinical_variable
( 86 87 1304 1305 I-clinical_variable
eGFR 87 91 1305 1309 I-clinical_variable
) 91 92 1309 1310 I-clinical_variable
of 93 95 1311 1313 O
> 96 97 1314 1315 O
50 98 100 1316 1318 B-upper_bound
ml 101 103 1319 1321 I-upper_bound
/ 103 104 1321 1322 I-upper_bound
min 104 107 1322 1325 I-upper_bound
as 108 110 1326 1328 O
calculated 111 121 1329 1339 O
by 122 124 1340 1342 O
the 125 128 1343 1346 O
Modification 129 141 1347 1359 B-clinical_variable
of 142 144 1360 1362 I-clinical_variable
Diet 145 149 1363 1367 I-clinical_variable
in 150 152 1368 1370 I-clinical_variable
Renal 153 158 1371 1376 I-clinical_variable
Disease 159 166 1377 1384 I-clinical_variable
( 167 168 1385 1386 I-clinical_variable
MDRD 168 172 1386 1390 I-clinical_variable
) 172 173 1390 1391 I-clinical_variable
equation 174 182 1392 1400 I-clinical_variable

Steroids 0 8 1401 1409 B-treatment
for 9 12 1410 1413 O
the 13 16 1414 1417 O
treatment 17 26 1418 1427 B-treatment
of 27 29 1428 1430 O
hypersensitivity 30 46 1431 1447 O
or 47 49 1448 1450 O
transfusion 50 61 1451 1462 O
reactions 62 71 1463 1472 O

Subject 0 7 1473 1480 O
agrees 8 14 1481 1487 O
not 15 18 1488 1491 O
to 19 21 1492 1494 O
participate 22 33 1495 1506 O
in 34 36 1507 1509 O
another 37 44 1510 1517 O
interventional 45 59 1518 1532 O
study 60 65 1533 1538 O
while 66 71 1539 1544 O
on 72 74 1545 1547 O
treatment 75 84 1548 1557 B-treatment

Subject 0 7 1558 1565 O
has 8 11 1566 1569 O
BCR 12 15 1570 1573 O
- 15 16 1573 1574 O
ABL 16 19 1574 1577 O
- 19 20 1577 1578 O
positive 20 28 1578 1586 O
leukemia 29 37 1587 1595 B-cancer
( 38 39 1596 1597 O
chronic 39 46 1597 1604 B-cancer
myelogenous 47 58 1605 1616 I-cancer
leukemia 59 67 1617 1625 I-cancer
in 68 70 1626 1628 O
blast 71 76 1629 1634 O
crisis 77 83 1635 1641 O
) 83 84 1641 1642 O

Subject 0 7 1643 1650 O
has 8 11 1651 1654 O
Fridericia 12 22 1655 1665 B-clinical_variable
- 22 23 1665 1666 I-clinical_variable
corrected 23 32 1666 1675 I-clinical_variable
QT 33 35 1676 1678 I-clinical_variable
interval 36 44 1679 1687 I-clinical_variable
( 45 46 1688 1689 I-clinical_variable
QTcF 46 50 1689 1693 I-clinical_variable
) 50 51 1693 1694 I-clinical_variable
> 52 53 1695 1696 O
450 54 57 1697 1700 B-lower_bound
ms 58 60 1701 1703 I-lower_bound
at 61 63 1704 1706 O
Screening 64 73 1707 1716 O
based 74 79 1717 1722 O
on 80 82 1723 1725 O
central 83 90 1726 1733 O
reading 91 98 1734 1741 O

Subject 0 7 1742 1749 O
has 8 11 1750 1753 O
Long 12 16 1754 1758 O
corrected 17 26 1759 1768 O
QT 27 29 1769 1771 B-chronic_disease
interval 30 38 1772 1780 I-chronic_disease
( 39 40 1781 1782 I-chronic_disease
QTc 40 43 1782 1785 I-chronic_disease
) 43 44 1785 1786 I-chronic_disease
Syndrome 45 53 1787 1795 I-chronic_disease
at 54 56 1796 1798 O
Screening 57 66 1799 1808 O

Subject 0 7 1809 1816 O
has 8 11 1817 1820 O
a 12 13 1821 1822 O
diagnosis 14 23 1823 1832 O
of 24 26 1833 1835 O
previously 27 37 1836 1846 O
- 37 38 1846 1847 O
untreated 38 47 1847 1856 O
de 48 50 1857 1859 B-cancer
novo 51 55 1860 1864 I-cancer
acute 56 61 1865 1870 I-cancer
myeloid 62 69 1871 1878 I-cancer
leukemia 70 78 1879 1887 I-cancer
( 79 80 1888 1889 I-cancer
AML 80 83 1889 1892 I-cancer
) 83 84 1892 1893 I-cancer
according 85 94 1894 1903 O
to 95 97 1904 1906 O
WHO 98 101 1907 1910 O
classification 102 116 1911 1925 O
( 117 118 1926 1927 O
2008 118 122 1927 1931 O
) 122 123 1931 1932 O
documented 124 134 1933 1943 O
within 135 141 1944 1950 O
28 142 144 1951 1953 B-upper_bound
days 145 149 1954 1958 I-upper_bound
prior 150 155 1959 1964 I-upper_bound
to 156 158 1965 1967 O
enrollment 159 169 1968 1978 O

Subject 0 7 1979 1986 O
has 8 11 1987 1990 O
active 12 18 1991 1997 O
hepatitis 19 28 1998 2007 B-chronic_disease
B 29 30 2008 2009 I-chronic_disease
or 31 33 2010 2012 I-chronic_disease
C 34 35 2013 2014 I-chronic_disease
, 35 36 2014 2015 O
or 37 39 2016 2018 O
other 40 45 2019 2024 O
active 46 52 2025 2031 O
hepatic 53 60 2032 2039 B-chronic_disease
disorder 61 69 2040 2048 I-chronic_disease

Subject 0 7 2049 2056 O
has 8 11 2057 2060 O
active 12 18 2061 2067 O
malignant 19 28 2068 2077 B-cancer
tumors 29 35 2078 2084 I-cancer
other 36 41 2085 2090 O
than 42 46 2091 2095 O
AML 47 50 2096 2099 B-cancer
or 51 53 2100 2102 O
myelodysplastic 54 69 2103 2118 B-cancer
syndrome 70 78 2119 2127 I-cancer
( 79 80 2128 2129 I-cancer
MDS 80 83 2129 2132 I-cancer
) 83 84 2132 2133 I-cancer

Subject 0 7 2134 2141 O
has 8 11 2142 2145 O
an 12 14 2146 2148 O
Eastern 15 22 2149 2156 B-clinical_variable
Cooperative 23 34 2157 2168 I-clinical_variable
Oncology 35 43 2169 2177 I-clinical_variable
Group 44 49 2178 2183 I-clinical_variable
( 50 51 2184 2185 I-clinical_variable
ECOG 51 55 2185 2189 I-clinical_variable
) 55 56 2189 2190 I-clinical_variable
performance 57 68 2191 2202 I-clinical_variable
status 69 75 2203 2209 I-clinical_variable
≤ 76 77 2210 2211 O
2 78 79 2212 2213 B-upper_bound

Subject 0 7 2214 2221 O
has 8 11 2222 2225 O
an 12 14 2226 2228 O
active 15 21 2229 2235 B-chronic_disease
uncontrolled 22 34 2236 2248 I-chronic_disease
infection 35 44 2249 2258 I-chronic_disease

Subject 0 7 2259 2266 O
has 8 11 2267 2270 O
any 12 15 2271 2274 O
condition 16 25 2275 2284 O
which 26 31 2285 2290 O
makes 32 37 2291 2296 O
the 38 41 2297 2300 O
subject 42 49 2301 2308 O
unsuitable 50 60 2309 2319 O
for 61 64 2320 2323 O
study 65 70 2324 2329 O
participation 71 84 2330 2343 O
( 85 86 2344 2345 O
e.g. 86 90 2345 2349 O
ophthalmic 91 101 2350 2360 B-chronic_disease
conditions 102 112 2361 2371 I-chronic_disease
such 113 117 2372 2376 O
as 118 120 2377 2379 O
advanced 121 129 2380 2388 O
cataracts 130 139 2389 2398 B-chronic_disease
) 139 140 2398 2399 O

Subject 0 7 2400 2407 O
has 8 11 2408 2411 O
clinically 12 22 2412 2422 O
active 23 29 2423 2429 O
central 30 37 2430 2437 B-cancer
nervous 38 45 2438 2445 I-cancer
system 46 52 2446 2452 I-cancer
leukemia 53 61 2453 2461 I-cancer

Subject 0 7 2462 2469 O
has 8 11 2470 2473 O
congestive 12 22 2474 2484 B-chronic_disease
heart 23 28 2485 2490 I-chronic_disease
failure 29 36 2491 2498 I-chronic_disease
New 37 40 2499 2502 B-clinical_variable
York 41 45 2503 2507 I-clinical_variable
Heart 46 51 2508 2513 I-clinical_variable
Association 52 63 2514 2525 I-clinical_variable
( 64 65 2526 2527 I-clinical_variable
NYHA 65 69 2527 2531 I-clinical_variable
) 69 70 2531 2532 I-clinical_variable
class 71 76 2533 2538 O
3 77 78 2539 2540 O
or 79 81 2541 2543 O
4 82 83 2544 2545 O
, 83 84 2545 2546 O
or 85 87 2547 2549 O
subject 88 95 2550 2557 O
with 96 100 2558 2562 O
a 101 102 2563 2564 O
history 103 110 2565 2572 O
of 111 113 2573 2575 O
congestive 114 124 2576 2586 O
heart 125 130 2587 2592 O
failure 131 138 2593 2600 O
NYHA 139 143 2601 2605 O
class 144 149 2606 2611 O
3 150 151 2612 2613 O
or 152 154 2614 2616 O
4 155 156 2617 2618 O
in 157 159 2619 2621 O
the 160 163 2622 2625 O
past 164 168 2626 2630 O
, 168 169 2630 2631 O
unless 170 176 2632 2638 O
a 177 178 2639 2640 O
screening 179 188 2641 2650 O
echocardiogram 189 203 2651 2665 B-treatment
performed 204 213 2666 2675 O
within 214 220 2676 2682 O
3 221 222 2683 2684 B-upper_bound
months 223 229 2685 2691 I-upper_bound
prior 230 235 2692 2697 I-upper_bound
to 236 238 2698 2700 O
study 239 244 2701 2706 O
entry 245 250 2707 2712 O
results 251 258 2713 2720 O
in 259 261 2721 2723 O
a 262 263 2724 2725 O
left 264 268 2726 2730 B-clinical_variable
ventricular 269 280 2731 2742 I-clinical_variable
ejection 281 289 2743 2751 I-clinical_variable
fraction 290 298 2752 2760 I-clinical_variable
that 299 303 2761 2765 O
is 304 306 2766 2768 O
≥ 307 308 2769 2770 O
45 309 311 2771 2773 B-lower_bound
% 311 312 2773 2774 I-lower_bound

Subject 0 7 2775 2782 O
has 8 11 2783 2786 O
disseminated 12 24 2787 2799 O
intravascular 25 38 2800 2813 B-chronic_disease
coagulation 39 50 2814 2825 I-chronic_disease
abnormality 51 62 2826 2837 I-chronic_disease
( 63 64 2838 2839 I-chronic_disease
DIC 64 67 2839 2842 I-chronic_disease
) 67 68 2842 2843 I-chronic_disease

Subject 0 7 2844 2851 O
has 8 11 2852 2855 O
had 12 15 2856 2859 O
major 16 21 2860 2865 O
surgery 22 29 2866 2873 B-treatment
within 30 36 2874 2880 O
4 37 38 2881 2882 B-upper_bound
weeks 39 44 2883 2888 I-upper_bound
prior 45 50 2889 2894 I-upper_bound
to 51 53 2895 2897 O
the 54 57 2898 2901 O
first 58 63 2902 2907 O
study 64 69 2908 2913 O
dose 70 74 2914 2918 O

Subject 0 7 2919 2926 O
has 8 11 2927 2930 O
hypokalemia 12 23 2931 2942 B-chronic_disease
and 24 27 2943 2946 O
hypomagnesemia 28 42 2947 2961 B-chronic_disease
at 43 45 2962 2964 O
Screening 46 55 2965 2974 O
( 56 57 2975 2976 O
defined 57 64 2976 2983 O
as 65 67 2984 2986 O
values 68 74 2987 2993 O
below 75 80 2994 2999 O
institutional 81 94 3000 3013 O
lower 95 100 3014 3019 O
limit 101 106 3020 3025 O
of 107 109 3026 3028 O
normal 110 116 3029 3035 O
[ 117 118 3036 3037 O
LLN 118 121 3037 3040 O
] 121 122 3040 3041 O
) 122 123 3041 3042 O

Subject 0 7 3043 3050 O
has 8 11 3051 3054 O
radiation 12 21 3055 3064 B-treatment
therapy 22 29 3065 3072 I-treatment
within 30 36 3073 3079 O
4 37 38 3080 3081 B-upper_bound
weeks 39 44 3082 3087 I-upper_bound
prior 45 50 3088 3093 I-upper_bound
to 51 53 3094 3096 O
the 54 57 3097 3100 O
first 58 63 3101 3106 O
study 64 69 3107 3112 O
dose 70 74 3113 3117 O

Subject 0 7 3118 3125 O
has 8 11 3126 3129 O
received 12 20 3130 3138 O
previous 21 29 3139 3147 B-treatment
therapy 30 37 3148 3155 I-treatment
for 38 41 3156 3159 O
AML 42 45 3160 3163 B-cancer

Subject 0 7 3164 3171 O
is 8 10 3172 3174 O
known 11 16 3175 3180 O
to 17 19 3181 3183 O
have 20 24 3184 3188 O
human 25 30 3189 3194 B-chronic_disease
immunodeficiency 31 47 3195 3211 I-chronic_disease
virus 48 53 3212 3217 I-chronic_disease
infection 54 63 3218 3227 I-chronic_disease

Subject 0 7 3228 3235 O
is 8 10 3236 3238 O
suitable 11 19 3239 3247 O
for 20 23 3248 3251 O
oral 24 28 3252 3256 B-treatment
administration 29 43 3257 3271 I-treatment
of 44 46 3272 3274 I-treatment
study 47 52 3275 3280 I-treatment
drug 53 57 3281 3285 I-treatment

Subject 0 7 3286 3293 O
requires 8 16 3294 3302 O
treatment 17 26 3303 3312 B-treatment
with 27 31 3313 3317 I-treatment
concomitant 32 43 3318 3329 I-treatment
drugs 44 49 3330 3335 I-treatment
that 50 54 3336 3340 O
are 55 58 3341 3344 O
strong 59 65 3345 3351 O
inducers 66 74 3352 3360 O
of 75 77 3361 3363 O
cytochrome 78 88 3364 3374 B-treatment
P450 89 93 3375 3379 I-treatment
( 94 95 3380 3381 I-treatment
CYP)3A 95 101 3381 3387 I-treatment

Subject 0 7 3388 3395 O
requires 8 16 3396 3404 O
treatment 17 26 3405 3414 B-treatment
with 27 31 3415 3419 O
concomitant 32 43 3420 3431 B-treatment
drugs 44 49 3432 3437 I-treatment
that 50 54 3438 3442 O
are 55 58 3443 3446 O
strong 59 65 3447 3453 O
inhibitors 66 76 3454 3464 O
or 77 79 3465 3467 O
inducers 80 88 3468 3476 O
of 89 91 3477 3479 O
P 92 93 3480 3481 O
glycoprotein 94 106 3482 3494 O
( 107 108 3495 3496 O
P 108 109 3496 3497 O
- 109 110 3497 3498 O
gp 110 112 3498 3500 O
) 112 113 3500 3501 O
with 114 118 3502 3506 O
the 119 122 3507 3510 O
exception 123 132 3511 3520 O
of 133 135 3521 3523 O
drugs 136 141 3524 3529 O
that 142 146 3530 3534 O
are 147 150 3535 3538 O
considered 151 161 3539 3549 O
absolutely 162 172 3550 3560 O
essential 173 182 3561 3570 O
for 183 186 3571 3574 O
the 187 190 3575 3578 O
care 191 195 3579 3583 O
of 196 198 3584 3586 O
the 199 202 3587 3590 O
subject 203 210 3591 3598 O

Subject 0 7 3599 3606 O
requires 8 16 3607 3615 O
treatment 17 26 3616 3625 B-treatment
with 27 31 3626 3630 I-treatment
concomitant 32 43 3631 3642 I-treatment
drugs 44 49 3643 3648 I-treatment
that 50 54 3649 3653 O
target 55 61 3654 3660 O
serotonin 62 71 3661 3670 O
5HT1R 72 77 3671 3676 O
or 78 80 3677 3679 O
5HT2BR 81 87 3680 3686 O
receptors 88 97 3687 3696 O
or 98 100 3697 3699 O
sigma 101 106 3700 3705 O
nonspecific 107 118 3706 3717 O
receptor 119 127 3718 3726 O
with 128 132 3727 3731 O
the 133 136 3732 3735 O
exception 137 146 3736 3745 O
of 147 149 3746 3748 O
drugs 150 155 3749 3754 O
that 156 160 3755 3759 O
are 161 164 3760 3763 O
considered 165 175 3764 3774 O
absolutely 176 186 3775 3785 O
essential 187 196 3786 3795 O
for 197 200 3796 3799 O
the 201 204 3800 3803 O
care 205 209 3804 3808 O
of 210 212 3809 3811 O
the 213 216 3812 3815 O
subject 217 224 3816 3823 O

Subject 0 7 3824 3831 O
was 8 11 3832 3835 O
diagnosed 12 21 3836 3845 O
as 22 24 3846 3848 O
acute 25 30 3849 3854 B-cancer
promyelocytic 31 44 3855 3868 I-cancer
leukemia 45 53 3869 3877 I-cancer
( 54 55 3878 3879 I-cancer
APL 55 58 3879 3882 I-cancer
) 58 59 3882 3883 I-cancer
or 60 62 3884 3886 O
AML 63 66 3887 3890 B-cancer
with 67 71 3891 3895 O
good 72 76 3896 3900 O
risk 77 81 3901 3905 O
cytogenetics 82 94 3906 3918 O
; 94 95 3918 3919 O
t(8;21 96 102 3920 3926 O
) 102 103 3926 3927 O
, 103 104 3927 3928 O
inv(16 105 111 3929 3935 O
) 111 112 3935 3936 O
or 113 115 3937 3939 O
t(16;16 116 123 3940 3947 O
) 123 124 3947 3948 O

Total 0 5 3949 3954 B-clinical_variable
serum 6 11 3955 3960 I-clinical_variable
bilirubin 12 21 3961 3970 I-clinical_variable
≤ 22 23 3971 3972 O
1.5 24 27 3973 3976 B-upper_bound
x 28 29 3977 3978 I-upper_bound
institutional 30 43 3979 3992 I-upper_bound
ULN 44 47 3993 3996 I-upper_bound

documented 0 10 3997 4007 O
surgically 11 21 4008 4018 O
sterile 22 29 4019 4026 O
or 30 32 4027 4029 O
status 33 39 4030 4036 O
post 40 44 4037 4041 O
hysterectomy 45 57 4042 4054 B-treatment
( 58 59 4055 4056 O
at 59 61 4056 4058 O
least 62 67 4059 4064 O
1 68 69 4065 4066 B-lower_bound
month 70 75 4067 4072 I-lower_bound
prior 76 81 4073 4078 I-lower_bound
to 82 84 4079 4081 O
Screening 85 94 4082 4091 O
) 94 95 4091 4092 O

must 0 4 4093 4097 O
agree 5 10 4098 4103 O
not 11 14 4104 4107 O
to 15 17 4108 4110 O
try 18 21 4111 4114 O
to 22 24 4115 4117 O
become 25 31 4118 4124 O
pregnant 32 40 4125 4133 B-pregnancy
during 41 47 4134 4140 O
the 48 51 4141 4144 O
study 52 57 4145 4150 O
and 58 61 4151 4154 O
for 62 65 4155 4158 O
180 66 69 4159 4162 B-upper_bound
days 70 74 4163 4167 I-upper_bound
after 75 80 4168 4173 O
the 81 84 4174 4177 O
final 85 90 4178 4183 O
study 91 96 4184 4189 B-treatment
drug 97 101 4190 4194 I-treatment
administration 102 116 4195 4209 O

must 0 4 4210 4214 O
have 5 9 4215 4219 O
a 10 11 4220 4221 O
negative 12 20 4222 4230 O
urine 21 26 4231 4236 O
pregnancy 27 36 4237 4246 B-pregnancy
test 37 41 4247 4251 O
at 42 44 4252 4254 O
Screening 45 54 4255 4264 O

must 0 4 4265 4269 O
use 5 8 4270 4273 B-contraception_consent
two 9 12 4274 4277 I-contraception_consent
forms 13 18 4278 4283 I-contraception_consent
of 19 21 4284 4286 I-contraception_consent
birth 22 27 4287 4292 I-contraception_consent
control 28 35 4293 4300 I-contraception_consent
* 35 36 4300 4301 O
( 37 38 4302 4303 O
at 38 40 4303 4305 O
least 41 46 4306 4311 O
one 47 50 4312 4315 O
of 51 53 4316 4318 O
which 54 59 4319 4324 O
must 60 64 4325 4329 O
be 65 67 4330 4332 O
a 68 69 4333 4334 O
barrier 70 77 4335 4342 B-contraception_consent
method 78 84 4343 4349 I-contraception_consent
) 84 85 4349 4350 O
starting 86 94 4351 4359 O
at 95 97 4360 4362 O
Screening 98 107 4363 4372 O
and 108 111 4373 4376 O
throughout 112 122 4377 4387 O
the 123 126 4388 4391 O
study 127 132 4392 4397 O
period 133 139 4398 4404 O
and 140 143 4405 4408 O
for 144 147 4409 4412 O
180 148 151 4413 4416 B-upper_bound
days 152 156 4417 4421 I-upper_bound
after 157 162 4422 4427 O
the 163 166 4428 4431 O
final 167 172 4432 4437 O
study 173 178 4438 4443 B-treatment
drug 179 183 4444 4448 I-treatment
administration 184 198 4449 4463 O

post 0 4 4464 4468 O
- 4 5 4468 4469 O
menopausal 5 15 4469 4479 O
( 16 17 4480 4481 O
defined 17 24 4481 4488 O
as 25 27 4489 4491 O
at 28 30 4492 4494 O
least 31 36 4495 4500 O
1 37 38 4501 4502 B-lower_bound
year 39 43 4503 4507 I-lower_bound
without 44 51 4508 4515 O
any 52 55 4516 4519 O
menses 56 62 4520 4526 O
) 62 63 4526 4527 O
prior 64 69 4528 4533 O
to 70 72 4534 4536 O
Screening 73 82 4537 4546 O

